The epigenetic basis for the aberrant expression of kallikreins in human cancers

Biological Chemistry

Volumn 387, Issue 6, 2006, Pages 795-799

  Pampalakis, Georgios ^a   Diamandis, Eleftherios P ^b,c   Sotiropoulou, Georgia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aberrant expression; Cancer; DNA methylation; Epigenetic regulation; Human tissue kallikreins

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIOLOGICAL MARKER; KALLIKREIN;

BREAST CANCER; CANCER CELL CULTURE; CANCER GENETICS; CHROMOSOME 19Q; CONFERENCE PAPER; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DOWN REGULATION; TANDEM REPEAT;

AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CPG ISLANDS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 33745676337     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.100     Document Type: Conference Paper

References (28)

1. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
2. Christophi, G.P., Isackson, P.J., Blaber, S., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J. Neurochem. 91, 1439-1449.
3. Evans, B.A., Yun, Z.X., Close, J.A., Tregear, G.W., Kitamura, N., Nakanishi, S., Callen, D.F., Baker, E., Hyland, V.J., Sutherland, G.R., and Richards, R.I. (1988). Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry 27, 3124-3129.
4. Gan, L., Lee, I., Smith, R., Argonza-Barrett, R., Lei, H., McCuaig, J., Moss, P., Paeper, B., and Wang, K. (2000). Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 257, 119-130.
5. Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A., Ashworth, L.K., and Clements, J.A. (2000). Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. 275, 37397-37406.
6. Johnstone, R.W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299.
7. Jones, P.A. and Baylin, S.B. (2002). The fundamental role of epigenetic events in cancer. Nat. Rev. Cancer 3, 415-428.
8. 5 in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur. J. Cancer 36, 780-786.
9. Li, B., Goyal, J., Dhar, S., Dimri, G., Evron, E., Sukumar, S., Wazer, E.D., and Band, V. (2001). CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 61, 8014-8021.
10. Lin, R., Nagai, Y., Sladek, R., Bastien, Y., Ho, J., Petrecca, K., Sotiropoulou, G., Diamandis, E.P., Hudson, T.J., and White, J.H. (2002). Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 16, 1243-1256.
11. Lyko, F. and Brown, R. (2005). DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 97, 1498-1506.
12. Nakamura, T., Mitsui, S., Okui, A., Kominami, K., Nomoto, T., Ukimura, O., Kawauchi, A., Miki, T., and Yamaguchi, N. (2001). Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in prostate cancer cell lines. Prostate 49, 72-78.
13. Palmer, H.G., Sanchez-Carbayo, M., Ordonez-Moran, P., Larriba, M.J., Cordon-Cardo, C., and Munoz, A. (2003). Genetic signatures of differentiation induced by 1α,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 63, 7799-7806.
14. Pampalakis, G., Kurlender, L., Diamandis, E.P., and Sotiropoulou, G. (2004). Cloning and characterization of novel isoforms of the human kallikrein 6 gene. Biochem. Biophys. Res. Commun. 320, 54-61.
15. Papsidero, L.D., Wang, M.C., Valenzuela, L.A., Murphy, G.P., and Chu, T.M. (1980). A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40, 2428-2432.
16. Qin, H., Kemp, J., Yip, M., Lam-Po-Tang, P.R.L., and Morris, B.J. (1991). Localization of human glandular kallikrein-1 gene to chromosome 19q13.3-13.4 by in situ hybridization. Hum. Hered. 41, 222-226.
17. Richards, R.I., Holman, K., Shen, Y., Kozman, H., Harley, H., Brook, D., Shaw, D. (1991). Human glandular kallikrein genes: genetic and physical mapping of the KLK1 locus using a highly polymorphic microsatellite PCR marker. Genomics 11, 77-82.
18. Riegman, P.H.J., Vlietstra, R.J., Klaassen, P., Van der Korput, J.A.G.M., Guerts van Kessel, A., Romijn, J.C., and Trapman, J. (1989). The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett. 247, 123-126.
19. Riegman, P.H.J., Vlietstra, R.J., Suurmeijer, L., Cleutjens, C.B.J.M., and Trapman, J. (1992). Characterization of the human kallikrein locus. Genomics 14, 6-11.
20. Rittenhouse, H.G., Finlay, J.A., Mikolajczyk, S.D., and Partin, A.W. (1988). Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci. 35, 275-368.
21. Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J.A., Barrios, M., Andreu, E.J., Prosper, F., Heiniger, A., and Torres, A. (2004). The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 18, 362-365.
22. Sidiropoulos, M., Pampalakis, G., Sotiropoulou, G., Katsaros, D., Diamandis, E.P. (2005). Downregulation of human kallikrein 10 (KLK10/NES1) gene by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumor Biol. 26, 324-336.
23. Wang, M.C., Valenzuela, L.A., Murphy, G.P., and Chu, T.M. (1977). Tissue specific and tumor specific antigens in human prostate. Fed. Proc. 36, 1254.
24. Wang, M.C., Valenzuela, L.A., Murphy, G.P., and Chu, T.M. (1979). Purification of a human prostate-specific antigen. Invest. Urol. 17, 159-163.
25. Wang, M.C., Papsidero, L.D., Kuriyama, M., Valenzuela, L.A., Murphy, G.P., and Chu, T.M. (1981). Prostate antigen: a new potential marker for prostatic cancer. Prostate 21, 89-96.
26. Xi, Z., Kaern, J., Davidson, B., Klokk, T.I., Risberg, B., Trope, C., and Saatcioglu, F. (2004). Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol. Oncol. 94, 80-85.
27. Yousef, G.M. and Diamandis, E.P. (2001). The new human tissue kallikrein gene family: structure, function and association to disease. Endocr. Rev. 22, 184-204.
28. Yousef, G.M., Chang, A., Scorilas, A., and Diamandis, E.P. (2000). Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys. Res. Commun. 16, 125-133.